By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Proteome Sciences said today that it has signed a non-exclusive license with Randox Laboratories for use of its stroke protein biomarker portfolio.

Randox will use the markers in products for early diagnosis of stroke and subsequent patient monitoring. The agreement provides Proteome Sciences with "seven-digit (US dollar) license and development milestones" as well as double-digit royalties on sales, the London, UK-based company said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.